Skyscape Web Viewer : Cancer Pharmacology: An Illustrated Manual of Anticancer Drugs : Main Index

View All
Mabs
MAC
prostate cancer 17α-hydroxylase/17-lyase (CYP17) inhibitors abiraterone and its prodrug, abiraterone acetate and rogen deprivation therapy and rogen receptor (AR) activation by dihydrotestosterone (DHT) apalutamide AR antagonists (antiand rogens) darolutamide enzalutamide GnRH agonists and antagonists overview schematic structure of GnRH agonist relative to native GnRH steroidal and nonsteroidal antiand rogens treatment goal
mammalian target of rapamycin (mTOR) Hormonal Therapies Alone and in Combinations for Treatment of Breast Cancer Transplant-Related Agents
mantle cell lymphoma (MCL) Answer 11.5 DNA Repair, Apoptotic Pathways, CDK Inhibitors Targeted Therapies (Small Molecules)
MAPK
marginal zone lymphoma (MZL) Answer 11.5 Targeted Therapies (Small Molecules)
maximal tolerated dose (MTD) Answer 16.1 Drug Approval and Regulatory Issues Question 16.2
maximum plasma concentration (Cmax)
MCL
MDR
MDSCs
MDSs
Mel
melphalan (Mel)
membrane attack complex (MAC)
MESNA
Me-THF
methotrexate (MTX) Answer 4.1 Answer 4.2 Answer 4.3 Answer 4.5 Antimetabolites: Antifolates Question 4.2 Question 4.3 Question 4.4 Question 4.5
methylenetetrahydrofolate (Me-THF)
MGMT
microsatellite instability (MSI)
minimal residual disease (MRD) Answer 13.1 Immunotherapeutics Including Vaccines, Bispecifics, CAR-T, and Checkpoint Inhibitors
mismatch repair deficiency (MMRd)
mitogen-activated protein kinase (MAPK)
MM
MMAE
MMF
MMRd
molecular pharmacological audit trial (MoPhAT)